AVCT.L

Avacta Group Plc
Avacta Group PLC - Block Listing Six Monthly Return
28th October 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7700J
Avacta Group PLC
28 October 2024
 

 

 

 

 

 

 


28 October 2024

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

 

Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,  today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 

Name of applicant:

Avacta Group plc

Name of scheme:

EMI scheme

Period of return:

From:

28 April 2024


27 October 2024

Balance of unallotted securities under scheme(s) from previous return:

803,006

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

527,626

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

275,380






 

Name of applicant:

Avacta Group plc

Name of scheme:

LTIP scheme

Period of return:

From:

28 April 2024


27 October 2024

Balance of unallotted securities under scheme(s):

9,719,257

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

3,806,000

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

5,913,257






 

Name of contact:

James Heseltine, Company Secretary

Telephone number of contact:

+ 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Michael Vinegrad, Group Communications Director

 

https://avacta.com/

Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm

www.peelhunt.com

 

ICR Healthcare

 

Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

avacta@consilium-comms.com

 

 

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

About AVA6000: FAP-enabled doxorubicin

The lead pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/.

AVA6103: FAP-enabled PDC targeting Topoisomerase I

AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability.

 

 

AVA7100: pre|CISION® FAP Affimer Drug Conjugate (AffDC)

 

AVA7100 is a pre|CISION®-enabled Affimer® drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer® molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload.

 

About Avacta Group plc - https://avacta.com/

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION® platform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPGPPUUPCGRM]]>
TwitterFacebookLinkedIn